Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Outcomes Convention Name November 7, 2024 4:30 PM ET
Firm Contributors
Panna Sharma – President and CEO
David Margrave – Chief Monetary Officer
Kishor Bhatia – Chief Scientific Officer
Operator
Good afternoon, and welcome to our Third Quarter 2024 earnings name. As a reminder, this name is being recorded, and all attendees are in a listen-only mode. We’ll open the decision for questions-and-answers after our administration’s presentation. A webcast replay of at present’s convention name will probably be obtainable on our web site at lanternpharma.com shortly after the decision.
We issued a press launch after market closed at present summarizing our monetary outcomes and progress throughout the corporate for the third quarter ended September 30, 2024. A duplicate of this launch is obtainable by means of our web site at lanternpharma.com, the place additionally, you will discover a hyperlink to the slide’s administration will probably be referencing on at present’s name.
We wish to remind everybody that remarks about future expectations, efficiency, estimates, and prospects represent forward-looking statements for functions of protected harbor provisions below the Non-public Securities Litigation Reform Act of 1995. Lantern Pharma cautions that these forward-looking statements are topic to dangers and uncertainties that will trigger precise outcomes to vary materially from these anticipated.
A variety of components may trigger precise outcomes to vary materially from these indicated by forward-looking statements, together with outcomes of medical trials and the influence of competitors. Further data regarding components that would trigger precise outcomes to vary materially from these within the forward-looking statements will be present in our annual report on type 10-Okay for the yr ended December 31, 2023, which is on file with the SEC and obtainable on our web site.
Ahead-looking statements made on this convention name are as of at present, November 7, 2024, and Lantern Pharma doesn’t intend to replace any of
